<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63191">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02283268</url>
  </required_header>
  <id_info>
    <org_study_id>071101</org_study_id>
    <secondary_id>2014-003575-38</secondary_id>
    <nct_id>NCT02283268</nct_id>
  </id_info>
  <brief_title>Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery</brief_title>
  <official_title>A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta US Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxalta US Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of recombinant von Willebrand
      factor (rVWF) with or without ADVATE in major and minor elective surgical procedures in
      adult patients with hereditary severe von Willebrand disease (VWD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemostatic efficacy as assessed by the investigator (hemophilia physician)</measure>
    <time_frame>24 hours after last peri-operative infusion or at completion of Day 14 visit, whichever occurs earlier</time_frame>
    <description>Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative actual versus predicted blood loss (assessed by the operating surgeon)</measure>
    <time_frame>Day 0 (at completion of surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemostatic efficacy score as assessed by the operating surgeon</measure>
    <time_frame>Day 0 (at completion of surgery)</time_frame>
    <description>Hemostatic efficacy will be rated on a scale of excellent - good - moderate - none.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily intra- and postoperative weight-adjusted dose of rVWF with or without ADVATE</measure>
    <time_frame>Through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of thrombotic events</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe allergic reactions (eg, anaphylaxis)</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of inhibitory and total binding antibodies to VWF</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of inhibitory antibodies to Factor VIII (FVIII)</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of antibodies to Chinese hamster ovary (CHO) proteins, mouse immunoglobulin G (IgG) or recombinant Furin (rFurin)</measure>
    <time_frame>Through study completion (ie, 14 days post surgery)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve from 0 to 72 hours post-infusion (AUC 0-72 h/dose)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the plasma concentration versus time curve from time 0 to infinity (AUC 0-∞ /dose)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Mean residence time (MRT)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Clearance (CL)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Incremental recovery (IR)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Elimination phase half-life (T1/2)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Volume of distribution at steady state (Vss)</measure>
    <time_frame>Within 30 minutes pre-infusion and up to 72 (± 2) hours post-infusion</time_frame>
    <description>This assessment is only required for subjects undergoing major surgery. Subjects will receive a PK infusion at a dose of 50±5 IU/kg rVWF:RCo within 42 days prior to surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Von Willebrand Disease</condition>
  <arm_group>
    <arm_group_label>Recombinant von Willebrand Factor (rVWF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery participants treated with Recombinant von Willebrand Factor (rVWF)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant von Willebrand Factor (rVWF)</intervention_name>
    <description>rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.</description>
    <arm_group_label>Recombinant von Willebrand Factor (rVWF)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of severe von Willebrand disease (VWD) as listed below and elective
             surgical procedure planned

               1. Type 1 (Von Willebrand factor : Ristocetin cofactor activity (VWF:RCo) &lt;20
                  IU/dL), or

               2. Type 2A (as verified by multimer pattern), Type 2B (as diagnosed by genotype),
                  Type 2N (FVIII:C&lt;10% and historically documented genetics), Type 2M, or

               3. Type 3 (Von Willebrand factor antigen (VWF:Ag) ≤ 3 IU/dL)

          -  VWD with a history of requiring substitution therapy with von Willebrand factor (VWF)
             concentrate to control bleeding

          -  If type 3 VWD (VWF Antigen /VWF:Ag ≤ 3 IU/dL), participant has a medical history of
             at least 20 exposure days to VWF/FVIII coagulation factor concentrates (including
             cryoprecipitate or fresh frozen plasma)

          -  If type 1 or type 2 VWD, participant has a medical history of 5 exposure days or a
             past major surgery requiring VWF/FVIII coagulation factor concentrates (including
             cryoprecipitate or fresh frozen plasma)

          -  Participant is at least 18 years of age

          -  If female of childbearing potential, participant presents with a negative pregnancy
             test

          -  If applicable, participant agrees to employ adequate birth control measures for the
             duration of the study

          -  Participant is willing and able to comply with the requirements of the protocol

        Exclusion Criteria:

          -  Diagnosis of pseudo VWD or another hereditary or acquired coagulation disorder (eg,
             qualitative and quantitative platelet disorders or elevated prothrombin time [PT] /
             international normalized ratio [INR] &gt; 1.4)

          -  History or presence of a VWF inhibitor at screening

          -  History or presence of a factor VIII (FVIII) inhibitor with a titer ≥ 0.4 BU
             (Nijmegen-modified Bethesda assay ) or ≥ 0.6 BU (by Bethesda assay)

          -  Known hypersensitivity to any of the components of the study drugs, such as to mouse
             or hamster proteins

          -  Medical history of immunological disorders, excluding seasonal allergic
             rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies

          -  Medical history of a thromboembolic event

          -  HIV positive with an absolute CD4 count &lt; 200/mm3

          -  Platelet count &lt; 100,000/mL

          -  Diagnosis of significant liver disease, as evidenced by, but not limited to, any of
             the following: serum alanine aminotransferase (ALT) 5 times the upper limit of
             normal; hypoalbuminemia; portal vein hypertension (eg. presence of otherwise
             unexplained splenomegaly, history of esophageal varices) or liver cirrhosis
             classified as Child B or C

          -  Diagnosis of renal disease, with a serum creatinine level ≥ 2 .5mg/dL

          -  Participant has been treated with an immunomodulatory drug, excluding topical
             treatment (eg, ointments, nasal sprays), within 30 days prior to signing the informed
             consent

          -  Participant is pregnant or lactating at the time informed content is obtained

          -  Participant has participated in another clinical study involving an investigational
             product (IP), other than rVWF with or without ADVATE, or investigational device
             within 30 days prior to enrollment or is scheduled to participate in another clinical
             study involving an IP or investigational device during the course of this study.
             However, eligible patients participating in the rVWF Prophylaxis Study (071301) may
             be enrolled.

          -  Progressive fatal disease and/or life expectancy of less than 3 months

          -  Participant is identified by the investigator as being unable or unwilling to
             cooperate with study procedures

          -  Participant suffers from a mental condition rendering him/her unable to understand
             the nature, scope and possible consequences of the study and/or evidence of an
             uncooperative attitude

          -  Participant is in prison or compulsory detention by regulatory and/or juridical order

          -  Participant is a member of the study team conducting this study or in a dependent
             relationship with one of the study team members. Dependent relationships include
             close relatives (ie, children, partner/spouse, siblings, parents) as well as
             employees.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur Sytkowski, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta US Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hemophilia &amp; Thrombosis Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami, Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blood Center of South East Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Perth Blood Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH - Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Careggi</name>
      <address>
        <city>Firenze (Florence)</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I Policlinico di Roma, Universitá di Roma La Sapienza</name>
      <address>
        <city>Rome</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Budgetary State Healthcare Institution (SHI) &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Barnaul</city>
        <zip>656024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSI Kirov Institute of Hematology and Blood Transfusion FMBA</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11490</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SI Institute of Blood Pathology and Transfusion Medicine of NAMSU</name>
      <address>
        <city>Lviv</city>
        <zip>79044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 14, 2016</lastchanged_date>
  <firstreceived_date>October 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
